|
|
Blood, 1 April 2004, Vol. 103, No. 7, pp. 2585-2592.
Prepublished online as a Blood First Edition Paper on November 26, 2003; DOI 10.1182/blood-2003-04-1127.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors
Nadine Haserück,
Wolfgang Erl,
Dharmendra Pandey,
Gabor Tigyi,
Philippe Ohlmann,
Catherine Ravanat,
Christian Gachet, and
Wolfgang Siess
From the Institute for Prevention of Cardiovascular Diseases, University of Munich, Munich, Germany; INSERM U311, EFS-Alsace, Strasbourg, France; and Department of Physiology, University of Tennessee Health Sciences Center, Memphis.
Despite the fact that lysophosphatidic acid (LPA) has been identified as a main platelet-activating lipid of mildly oxidized low-density lipoprotein (LDL) and human atherosclerotic lesions, it remains unknown whether it is capable of activating platelets in blood. We found that LPA at concentrations slightly above plasma levels induces platelet shape change, aggregation, and platelet-monocyte aggregate formation in blood. 1-alkyl-LPA (16:0 fatty acid) was almost 20-fold more potent than 1-acyl-LPA (16:0). LPA directly induced platelet shape change in blood and platelet-rich plasma obtained from all blood donors. However, LPA-stimulated platelet aggregation in blood was donor dependent. It could be completely blocked by apyrase and antagonists of the platelet adenosine diphosphate (ADP) receptors P2Y1 and P2Y12. These substances also inhibited LPA-induced aggregation of platelet-rich plasma and aggregation and serotonin secretion of washed platelets. These results indicate a central role for ADP-mediated P2Y1 and P2Y12 receptor activation in supporting LPA-induced platelet aggregation. Platelet aggregation and platelet-monocyte aggregate formation stimulated by LPA was insensitive to inhibition by aspirin. We conclude that LPA at concentrations approaching those found in vivo can induce platelet shape change, aggregation, and platelet-monocyte aggregate formation in whole blood and suggest that antagonists of platelet P2Y1 and P2Y12 receptors might be useful preventing LPA-elicited thrombus formation in patients with cardiovascular diseases.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Z. Pamuklar, J. S. Lee, H.-Y. Cheng, M. Panchatcharam, S. Steinhubl, A. J. Morris, R. Charnigo, and S. S. Smyth
Individual Heterogeneity in Platelet Response to Lysophosphatidic Acid: Evidence for a Novel Inhibitory Pathway
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2008;
28(3):
555 - 561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Osborn, C. Dahlgren, J. H. Hartwig, and T. P. Stossel
Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin
Am J Physiol Cell Physiol,
April 1, 2007;
292(4):
C1323 - C1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Michno, H. Bielarczyk, T. Pawelczyk, A. Jankowska-Kulawy, J. Klimaszewska, and A. Szutowicz
Alterations of Adenine Nucleotide Metabolism and Function of Blood Platelets in Patients With Diabetes
Diabetes,
February 1, 2007;
56(2):
462 - 467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-M. Chung, O.-N. Bae, K.-M. Lim, J.-Y. Noh, M.-Y. Lee, Y.-S. Jung, and J.-H. Chung
Lysophosphatidic Acid Induces Thrombogenic Activity Through Phosphatidylserine Exposure and Procoagulant Microvesicle Generation in Human Erythrocytes
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2007;
27(2):
414 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Penz, A. J. Reininger, R. Brandl, P. Goyal, T. Rabie, I. Bernlochner, E. Rother, C. Goetz, B. Engelmann, P. A. Smethurst, et al.
Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI
FASEB J,
June 1, 2005;
19(8):
898 - 909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke
Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
J. Lipid Res.,
March 1, 2005;
46(3):
389 - 403.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
